Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

What influences clinicians' decisions about ADHD medication? Initial data from the Influences on Prescribing for ADHD Questionnaire (IPAQ).

Kovshoff H, Vrijens M, Thompson M, Yardley L, Hodgkins P, Sonuga-Barke EJ, Danckaerts M.

Eur Child Adolesc Psychiatry. 2013 Sep;22(9):533-42. doi: 10.1007/s00787-013-0393-y. Epub 2013 Mar 2.

PMID:
23455602
2.

Paediatricians' decision making about prescribing stimulant medications for children with attention-deficit/hyperactivity disorder.

Chow SJ, Sciberras E, Gillam LH, Green J, Efron D.

Child Care Health Dev. 2014 May;40(3):301-8. doi: 10.1111/cch.12036. Epub 2013 Feb 27.

PMID:
23445484
3.

Physician perceptions of the use of medications for attention deficit hyperactivity disorder.

Stockl KM, Hughes TE, Jarrar MA, Secnik K, Perwien AR.

J Manag Care Pharm. 2003 Sep-Oct;9(5):416-23.

4.
6.

Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed.

Preen DB, Calver J, Sanfilippo FM, Bulsara M, Holman CD.

Aust N Z J Public Health. 2007 Apr;31(2):120-6.

PMID:
17461001
7.

A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM, Onyango AN, Forehand G, Nguyen A, Waxmonsky J.

Pediatrics. 1999 Apr;103(4):e43.

PMID:
10103335
8.

National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.

Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS.

J Clin Psychiatry. 2008 Jan;69(1):131-40.

PMID:
18312048
9.

Are stimulants overprescribed for youths with ADHD?

Safer DJ.

Ann Clin Psychiatry. 2000 Mar;12(1):55-62. Review.

PMID:
10798827
10.

The decisions regarding ADHD management (DRAMa) study: uncertainties and complexities in assessment, diagnosis and treatment, from the clinician's point of view.

Kovshoff H, Williams S, Vrijens M, Danckaerts M, Thompson M, Yardley L, Hodgkins P, Sonuga-Barke EJ.

Eur Child Adolesc Psychiatry. 2012 Feb;21(2):87-99. doi: 10.1007/s00787-011-0235-8. Epub 2011 Dec 18.

PMID:
22180052
11.
12.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303
13.

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.

Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.

Pediatrics. 2003 Nov;112(5):e404.

PMID:
14595084
14.

Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.

Huang YS, Guilleminault C, Li HY, Yang CM, Wu YY, Chen NH.

Sleep Med. 2007 Jan;8(1):18-30. Epub 2006 Dec 6.

PMID:
17157069
15.

Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder.

Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, Zarin DA.

Arch Pediatr Adolesc Med. 1999 Dec;153(12):1257-63.

PMID:
10591302
16.
17.

Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings.

Breuer D, Görtz-Dorten A, Rothenberger A, Döpfner M.

Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2:S289-96. doi: 10.1007/s00787-011-0206-0.

18.

Co-morbidity and patterns of care in stimulant-treated children with ADHD in the Netherlands.

Faber A, Kalverdijk LJ, de Jong-van den Berg LT, Hugtenburg JG, Minderaa RB, Tobi H.

Eur Child Adolesc Psychiatry. 2010 Feb;19(2):159-66. doi: 10.1007/s00787-009-0075-y. Epub 2009 Nov 6.

19.
20.

To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?

van de Loo-Neus GH, Rommelse N, Buitelaar JK.

Eur Neuropsychopharmacol. 2011 Aug;21(8):584-99. doi: 10.1016/j.euroneuro.2011.03.008. Epub 2011 May 6. Review.

PMID:
21530185

Supplemental Content

Support Center